Active	Status	Sponsor type	Region	Phase	Filter
3 Active 3 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
André, Marc
DALY 2-EU, NCT04844866 / 2020-003908-14: Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients	Active, not recruiting	2	168	Europe, RoW	MB-CART2019.1, R-GemOx or BR plus polatuzumab vedotin, Rituximab, Gemcitabine, Oxaliplatin, Polatuzumab vedotin, Bendamustine, Rituximab	Miltenyi Biomedicine GmbH, ICON plc	Diffuse Large B-cell Lymphoma	12/24	07/29
BEHCETBIOT, NCT04959435: Understanding the Role of Oral Microbiota in Behçet's Disease	Completed	N/A	66	Europe	biological samples collection	University Hospital, Clermont-Ferrand	Behçet Disease, Physiopathology, Microbiota, Oral Microbiota	06/24	06/24
CHANGE, NCT04732156: Detection of ISUP≥2 Prostate Cancers Using Multiparametric MRI: Prospective Multicenter Comparison of the PI-RADS Score and an Artificial Intelligence System	Recruiting	N/A	420	Europe	Blood sample, Follow up questionnaire, Human reading of prostate MR images (PI-RADSv2.1).	Hospices Civils de Lyon	Prostate Cancer	06/26	06/26